BeOne Medicines (NASDAQ:ONC) Director Sells $65,635.20 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Margaret Dugan sold 212 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $309.60, for a total transaction of $65,635.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Down 0.9%

Shares of ONC opened at $287.92 on Friday. The stock has a market capitalization of $31.59 billion, a P/E ratio of 64.41 and a beta of 0.50. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The firm has a fifty day simple moving average of $302.03 and a two-hundred day simple moving average of $320.68. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. On average, research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

Several institutional investors and hedge funds have recently modified their holdings of ONC. Bank of America Corp DE purchased a new stake in shares of BeOne Medicines in the 2nd quarter worth about $67,657,000. Man Group plc purchased a new stake in shares of BeOne Medicines in the 2nd quarter worth about $59,031,000. Capital International Investors lifted its position in shares of BeOne Medicines by 3.3% in the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after purchasing an additional 161,052 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of BeOne Medicines in the 2nd quarter worth about $38,337,000. Finally, First Trust Advisors LP lifted its position in shares of BeOne Medicines by 91.9% in the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after purchasing an additional 115,601 shares during the period. 48.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Guggenheim increased their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and dropped their price target for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Leerink Partners raised their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Finally, Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $389.15.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.